Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy
Abstract Background The concurrent presence of COVID-19 infection in advanced cancer patients has increased the mortality since the compromised immunity was inevitably worsen. The role and clinical impact of autologous adoptive T cell immunotherapy (ACT) designed for anti-cancer treatment were not k...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Infectious Agents and Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13027-025-00654-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849737817234604032 |
|---|---|
| author | Congcong Li Dazhao Xu Linyao Lu Shu Peng Haiyang Zhao Chuxiong Zeng Lina Hu Xianzhi Guo Li Liu Feifei Huo Xiumei Rong Zhenying Geng Ping Lin Xinna Zhou Xiaoli Wang Amy Hobeika Michael A. Morse Herbert Kim Lyerly Jun Ren |
| author_facet | Congcong Li Dazhao Xu Linyao Lu Shu Peng Haiyang Zhao Chuxiong Zeng Lina Hu Xianzhi Guo Li Liu Feifei Huo Xiumei Rong Zhenying Geng Ping Lin Xinna Zhou Xiaoli Wang Amy Hobeika Michael A. Morse Herbert Kim Lyerly Jun Ren |
| author_sort | Congcong Li |
| collection | DOAJ |
| description | Abstract Background The concurrent presence of COVID-19 infection in advanced cancer patients has increased the mortality since the compromised immunity was inevitably worsen. The role and clinical impact of autologous adoptive T cell immunotherapy (ACT) designed for anti-cancer treatment were not known in such circumstances. The safety and potential immune reconstitution of concurrent ACT in advanced cancer patients with active COVID-19 infection have yet unknown as well. The effect of infused ACT on the symptom severity manifestation should be summarized. Methods In this respectively clinical observation study, patients were non-randomized enrolled from the two centers according to the regular therapeutic plans including stage IV cancer patients for scheduled ACT, chemotherapy, cancer patients with symptomatic COVID-19 but without ACT, neither cancer or non-ACT but symptomatic cases of COVID-19 infection. We have incorporated the age-adjusted Charlson comorbidity index (aCCI) for each patient to compare the prognosis of the three groups. All patients were planned for the scheduled standard anti-cancer therapeutic considerations, chemotherapy plus ACT as planned as well as the supportive care.The clinical efficacy and impact of ACT on cancer patients within the 3 months from the peripheral blood apheresis, dendritic cell (DC) and cytokine induced killer T cell (CIK-T ) infusion and subsequent co-existence of COVID-19 infection were recorded as the primary objective. During the same period, the cancer cases without ACT and others were collected to compare the occurrence of both severe and death rate respectively. Results There were 123 patients (35 of ACT, 23 of non-ACT, 65 of non-cancer) with similar aCCI. There were similar cohort-level COVID-19 in-hospital case fatality rates consistent with previously reported data for non-cancer (26.2%, 17/65) and non-ACT cancer (52.2%, 12/23) among those admitted severe cases after the adjustment.There were little overlapped adverse reactions during the ACT therapeutic period even in the presence of active COVID-19 infection. No death case was occurred (0/35) when those exposed to ACT regimen. Cancer patients receiving ACT had a shorter mean time to alleviation of symptoms compared with non-ACT and non-cancer (4.46 versus 16.88 and 17.90 days respectively) as well as the lowered severity incidence of symptoms (P = 0.0010). The infused ACT has not significant impact on peripheral blood count whereas the amount of CD3−CD16+CD56+ NK cells increased (P = 0.0017). The quantity of infused ACT was favorable for augmentation of possibility of severe to mild symptom shift. Conclusions These data demonstrate the clinical safety profiles while ACT infusions with active COVID-19 infection.The intervention of ACT for cancer patients could generate the benefit for symptom alleviation with improved recovery time. The concurrent ACT for advanced cancer patients during such infectious pandemic might simultaneously leverage and reduce the risk of immune compromised situation for subsequent chemotherapy complications. |
| format | Article |
| id | doaj-art-8492cc0d68c8480f9ed82f0e6534d9fc |
| institution | DOAJ |
| issn | 1750-9378 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Infectious Agents and Cancer |
| spelling | doaj-art-8492cc0d68c8480f9ed82f0e6534d9fc2025-08-20T03:06:48ZengBMCInfectious Agents and Cancer1750-93782025-04-0120111110.1186/s13027-025-00654-2Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapyCongcong Li0Dazhao Xu1Linyao Lu2Shu Peng3Haiyang Zhao4Chuxiong Zeng5Lina Hu6Xianzhi Guo7Li Liu8Feifei Huo9Xiumei Rong10Zhenying Geng11Ping Lin12Xinna Zhou13Xiaoli Wang14Amy Hobeika15Michael A. Morse16Herbert Kim Lyerly17Jun Ren18Department of Medical Oncology, Fudan University Pudong Medical CenterDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of SciencesDepartment of Medical Oncology, Fudan University Pudong Medical CenterDepartment of Medical Oncology, Fudan University Huadong Medical CenterDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of SciencesDepartment of Medical Oncology, Fudan University Pudong Medical CenterDepartment of Medical Oncology, Fudan University Pudong Medical CenterDepartment of Medical Oncology, Fudan University Pudong Medical CenterDepartment of Medical Oncology, Fudan University Pudong Medical CenterDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of SciencesDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of SciencesDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of SciencesDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of SciencesCenter of Clinical Trials & Management, Beijing Shijitan Hospital, Capital Medical University Cancer CenterDepartment of Medical Oncology, Beijing Shijitan Hospital, Capital Medical University Cancer CenterDepartment of Surgery, Duke University Medical CenterDepartment of Medicine, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Medical Oncology, Fudan University Pudong Medical CenterAbstract Background The concurrent presence of COVID-19 infection in advanced cancer patients has increased the mortality since the compromised immunity was inevitably worsen. The role and clinical impact of autologous adoptive T cell immunotherapy (ACT) designed for anti-cancer treatment were not known in such circumstances. The safety and potential immune reconstitution of concurrent ACT in advanced cancer patients with active COVID-19 infection have yet unknown as well. The effect of infused ACT on the symptom severity manifestation should be summarized. Methods In this respectively clinical observation study, patients were non-randomized enrolled from the two centers according to the regular therapeutic plans including stage IV cancer patients for scheduled ACT, chemotherapy, cancer patients with symptomatic COVID-19 but without ACT, neither cancer or non-ACT but symptomatic cases of COVID-19 infection. We have incorporated the age-adjusted Charlson comorbidity index (aCCI) for each patient to compare the prognosis of the three groups. All patients were planned for the scheduled standard anti-cancer therapeutic considerations, chemotherapy plus ACT as planned as well as the supportive care.The clinical efficacy and impact of ACT on cancer patients within the 3 months from the peripheral blood apheresis, dendritic cell (DC) and cytokine induced killer T cell (CIK-T ) infusion and subsequent co-existence of COVID-19 infection were recorded as the primary objective. During the same period, the cancer cases without ACT and others were collected to compare the occurrence of both severe and death rate respectively. Results There were 123 patients (35 of ACT, 23 of non-ACT, 65 of non-cancer) with similar aCCI. There were similar cohort-level COVID-19 in-hospital case fatality rates consistent with previously reported data for non-cancer (26.2%, 17/65) and non-ACT cancer (52.2%, 12/23) among those admitted severe cases after the adjustment.There were little overlapped adverse reactions during the ACT therapeutic period even in the presence of active COVID-19 infection. No death case was occurred (0/35) when those exposed to ACT regimen. Cancer patients receiving ACT had a shorter mean time to alleviation of symptoms compared with non-ACT and non-cancer (4.46 versus 16.88 and 17.90 days respectively) as well as the lowered severity incidence of symptoms (P = 0.0010). The infused ACT has not significant impact on peripheral blood count whereas the amount of CD3−CD16+CD56+ NK cells increased (P = 0.0017). The quantity of infused ACT was favorable for augmentation of possibility of severe to mild symptom shift. Conclusions These data demonstrate the clinical safety profiles while ACT infusions with active COVID-19 infection.The intervention of ACT for cancer patients could generate the benefit for symptom alleviation with improved recovery time. The concurrent ACT for advanced cancer patients during such infectious pandemic might simultaneously leverage and reduce the risk of immune compromised situation for subsequent chemotherapy complications.https://doi.org/10.1186/s13027-025-00654-2Autologous adoptive cellular immunotherapyCOVID-19 infectionSafety. |
| spellingShingle | Congcong Li Dazhao Xu Linyao Lu Shu Peng Haiyang Zhao Chuxiong Zeng Lina Hu Xianzhi Guo Li Liu Feifei Huo Xiumei Rong Zhenying Geng Ping Lin Xinna Zhou Xiaoli Wang Amy Hobeika Michael A. Morse Herbert Kim Lyerly Jun Ren Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy Infectious Agents and Cancer Autologous adoptive cellular immunotherapy COVID-19 infection Safety. |
| title | Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy |
| title_full | Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy |
| title_fullStr | Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy |
| title_full_unstemmed | Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy |
| title_short | Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy |
| title_sort | clinical impact of concurrent autologous adoptive t cells immunotherapy in active covid 19 infected cancer patients for chemotherapy |
| topic | Autologous adoptive cellular immunotherapy COVID-19 infection Safety. |
| url | https://doi.org/10.1186/s13027-025-00654-2 |
| work_keys_str_mv | AT congcongli clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT dazhaoxu clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT linyaolu clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT shupeng clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT haiyangzhao clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT chuxiongzeng clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT linahu clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT xianzhiguo clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT liliu clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT feifeihuo clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT xiumeirong clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT zhenyinggeng clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT pinglin clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT xinnazhou clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT xiaoliwang clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT amyhobeika clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT michaelamorse clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT herbertkimlyerly clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy AT junren clinicalimpactofconcurrentautologousadoptivetcellsimmunotherapyinactivecovid19infectedcancerpatientsforchemotherapy |